Alzamend Neuro, Inc.
ALZN
$1.86
-$0.03-1.59%
NASDAQ
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.39M | 3.06M | 3.29M | 3.08M | 3.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.03M | 5.87M | 6.23M | 4.50M | 4.21M |
| Operating Income | -7.03M | -5.87M | -6.23M | -4.50M | -4.21M |
| Income Before Tax | -7.04M | -5.88M | -6.24M | -4.51M | -4.23M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.04 | -5.88 | -6.24 | -4.51 | -4.23 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.04M | -5.88M | -6.24M | -4.51M | -4.23M |
| EBIT | -7.03M | -5.87M | -6.23M | -4.50M | -4.21M |
| EBITDA | -6.94M | -5.79M | -6.17M | -4.45M | -4.16M |
| EPS Basic | -4.59 | -5.76 | -8.94 | -19.08 | -27.78 |
| Normalized Basic EPS | -2.35 | -3.05 | -5.03 | -11.37 | -17.33 |
| EPS Diluted | -4.59 | -5.76 | -8.94 | -19.08 | -27.78 |
| Normalized Diluted EPS | -2.35 | -3.05 | -5.03 | -11.37 | -17.33 |
| Average Basic Shares Outstanding | 10.00M | 6.81M | 3.82M | 1.80M | 1.17M |
| Average Diluted Shares Outstanding | 10.00M | 6.81M | 3.82M | 1.80M | 1.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |